China Antihypertensive Trial in Acute Ischemic Stroke II (CATIS-2): rationale and design.

ABSTRACT:

Backgrounds

Increased blood pressure (BP) for patients who had an acute ischaemic stroke is associated with poor functional outcome, however the optimal timing of antihypertensive therapy is unknown.

Aims

We aim to compare early antihypertensive treatment to delayed antihypertensive treatment for reducing the risk of composite major disability and mortality at 3 months in acute ischaemic stroke.

Design

The China Antihypertensive Trial in Acute Ischemic Stroke II (CATIS-2) trial is a multicentre, randomised, open-label, blinded-endpoints trial that will be conducted in 100 hospitals in China. The primary outcome is the composite of death and major disability (modified Rankin Scale score ≥3) at 3 months of randomisation. Antihypertensive treatment will be received immed

SUBMITTER: Liu L 

PROVIDER: S-EPMC8258043 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature